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Introduction
Nevirapine (NVP), the first non-nucleoside reverse-tran-
scriptase inhibitor introduced in clinical practice, is still 
included in antiretroviral regimens used in low-income 
countries due to its efficacy, including its use in prevention 
of mother to child transmission (PMTCT), good tolerability 
and relatively low cost.1 In high-income countries, NVP is 
no more included among preferred antiretroviral regimens, 
but it remains a valid option in simplification strategy of 
selected patients due to its favorable metabolic profile.2,3
Early onset of skin rash and hepatotoxicity, which may be 
severe in nature, and a low genetic barrier to resistance are 
the principal factors that limited NVP use.4 NVP is mainly 
metabolized by cytochrome P 450 2B6 (CYP2B6) and, to a 
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lesser degree, by CYP3A isoforms.5 Single-nucleotide poly-
morphisms (SNPs) in the genes encoding these enzymes 
have been shown to influence NVP pharmacokinetics in dif-
ferent ethnic populations.6,7 Furthermore, CYP3A5 is more 
commonly expressed in African populations and may affect 
NVP exposure.8 An association between CYP2B6 polymor-
phisms, body weight and NVP plasma concentration has also 
been observed in patients followed in European countries.9
The availability of pharmacogenetic testing opens the 
possibility of therapy personalization in HIV patients. The 
pharmacogenetic information can help to ensure the right 
dose for the single patient but also broader therapeutic strate-
gies in different ethnic groups, according to the prevalence 
of SNPs. By now, only few data are available on the effect of 
CYP2B6 and CYP3A4 and CYP3A5 polymorphisms on 
NVP plasma concentrations in the Caucasian population.
Our aim was to assess the impact of CYP2B6 and 
CYP3A4/A5 polymorphisms on NVP plasma concentrations 
in a prevalent Caucasian population.
Methods
Clinical data of all HIV-positive patients who were followed 
at the Infectious Diseases Unit, DIBIC Luigi Sacco, 
University of Milan between January 2000 and December 
2015 were retrospectively analyzed. All patients with at least 
one NVP plasma trough (Cmin) determination were included 
in the analysis. The first NVP Cmin sample was collected in 
2011. Patients must be on a stable NVP-based regimen at a 
daily dose of 400  mg once a day and must have optimal 
adherence to antiretroviral therapies verified through direct 
questioning during every outpatient visits. Data on self-
reporting adherence to antiretroviral drugs were also matched 
with data from our Pharmacy Department in order to verify 
antiretroviral drug refill, which would cover the time between 
two visits.
Subjects <18  years of age and those who had received 
NVP concomitantly with rifampicin or azoles were excluded 
from the study. Patients who did not reach the steady state 
for NVP trough concentration were excluded from the analy-
sis. Patients’ demographic and clinical data at the time of 
NVP plasma trough (Cmin) determination included gender, 
age, ethnicity, hepatitis C virus (HCV) and hepatitis B virus 
(HBV) coinfection, HIV-RNA, backbone antiretrovirals, 
aspartate aminotransferase (AST) and alanine aminotrans-
ferase (ALT) levels.
For the pharmacokinetic analyses, blood trough samples 
drawn into ethylenediaminetetraacetic acid (EDTA)-
containing vacutainers® were collected from all subjects 
close to the next NVP intake (a time window of ±30  min was 
directly verified by the nurse staff and considered as accept-
able). NVP plasma concentrations were measured by high-
performance liquid chromatography with photodiode array 
(PDA) detection.10 NVP plasma concentration were classi-
fied as <3000  ng/mL (below therapeutic range), 3000–6000 
ng/mL (therapeutic range) and >6000  ng/mL (above thera-
peutic range). This cut-off point was established accordingly 
to the steady-state trough concentration achieved in the phar-
macokinetic curve, as previously reported.11,12
All patients were tested for CYP2B6 c.516 G>T 
rs3745274 (wild type: GG; variants: GT and TT), 
CYP3A4*22C>T rs35599367 and CYP3A5*3 A>G 
rs776746 polymorphisms. Genomic DNA was isolated from 
peripheral blood cells using an automatic DNA extraction 
system (Maxwell® 16 System; Promega) following the man-
ufacturer’s instructions. The genotypes were determined by 
real-time polymerase chain reaction (PCR), using a panel of 
LightSNiP from TIB-MOLBIOL (assays based on 
SimpleProbe®). At the end of the amplification, a melting 
curve analysis was carried out (LightCycler 480; Roche).
Statistical analysis
The sample size calculation was based on the primary end-
point, that is, NVP concentrations in patients with GG and 
GT/TT genotypes of CYP2B6 rs3745274. After assuming an 
approximate standard deviation in the first group of 1400  ng/
mL, in the second group of 2400  ng/mL and a ratio between 
the two samples of 1, at least 62 patients were required for 
each group to evidence a minimal difference of 1000  ng/mL 
between the mean of the two groups. This sample estimate 
gave our analysis a power of 80% and a significant level of 
5%.13 Sample size had been calculated with the τ test.
NVP concentration in patients with different genotypes 
was compared by Kruskal–Wallis Test. For patients with 
multiple NVP concentration determinations, the first availa-
ble value was considered. CYP2B6 c.516 G>T rs3745274 
was analyzed alone, whereas CYP3A4 and CYP3A5 were 
analyzed combined for a more comprehensive functional 
evaluation.14,15
Univariate and multivariate linear regression analyses 
were carried out considering NVP Cmin as the dependent 
variable and genetic polymorphisms and clinical characteris-
tics, such as weight, age, sex, ethnicity, HCV and HBV status 
and backbone antiretrovirals, as independent variables. A 
general linear model to analyze the effect of independent 
variables on NVP concentrations was also applied. NVP 
concentrations were log-transformed in order to comply with 
the model requirements.
Statistical significance was defined at two-sided p value 
<0.05. SAS software version 9.3 was used to perform statis-
tical analysis. The protocol was approved by our ethics com-
mittee (Comitato Etico Interaziendale, Milano, Area 1); all 
subjects signed a dedicated informed consent.
Results
Patients’ characteristics
A total of 143 patients were evaluated, of whom 128 (89.5%) 
were drug-experienced, whereas 15 (10.5%) subjects started 
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NVP within their first-line regimen. Most of the patients 
were males (61.5%) and Caucasian (92.3%) with a median 
age of 47.7  years (interquartile range (IQR)  =  42.5–52.8 
years) and a median body mass index (BMI) of 23.1  kg/m2 
(IQR  =  20.8–24.5  kg/m2); a total of 32 (22.4%) patients 
were HCV coinfected (Table 1).
NVP plasma concentration
Overall, the patients underwent NVP Cmin determination 
after a median time of 82  months (IQR  =  44–117  months) 
from NVP start. NVP Cmin varied from 1571 to 14,189  ng/
mL (median  =  5063  ng/mL, IQR  =  3915–6854). In all, 8 
patients (5.6%) showed a NVP Cmin  <  3000  ng/mL, whereas 
61 (42.7%) showed a NVP Cmin  >  6000  ng/mL (Table 2). 
Patients with NVP Cmin  >  6000  ng/mL were significantly 
older (49.3  years, IQR  =  43.4–56.0) as compared to patients 
with NVP Cmin between 3000 and 6000  ng/mL (46.9  years, 
IQR  =  40.7–52.2) or <3000  ng/mL (43.1  years, IQR  = 
36.3–46.1; p  =  0.031). No significant differences were 
found in the rate of virological control (HIV-RNA  <  37 
copies/mL) at the time of NVP Cmin determination between 
patients with NVP Cmin  <  3000  ng/mL and those with NVP 
Cmin  =  3000–6000  ng/mL or >6000  ng/mL (87.5% vs 
95.9% vs 95.1%, respectively; p  =  0.499). Moreover, no 
differences were also observed regarding median AST and 
ALT levels in patients with NVP Cmin  >  6000  ng/mL when 
compared to patients with lower NVP Cmin levels. A trend 
was observed in the different strata regarding HCV coinfec-
tion with a higher percentage of patients resulting HCV 
coinfected in patients with NVP Cmin  >  6000  ng/mL when 
compared to patients with NVP Cmin  =  3000–6000  ng/mL 
and NVP Cmin  <  3000  ng/mL (29.5% vs 18.9% vs 0.0%, 
respectively; p  =  0.106).
The median NVP Cmin significantly differed in patients 
with different CYP2B6 genotypes (Figure 1). In particular, 
patient with GG genotypes of CYP2B6 rs3745274 showed 
significantly lower median NVP Cmin concentration (4553 
ng/mL, IQR  =  3653–6085) when compared to patient with 
GT (6268  ng/mL, IQR  =  4200–7559) and TT (6441  ng/mL, 
IQR  =  6311–9154) genotypes (p  <  0.001). No patients with 
TT genotype showed NVP Cmin  <  3000  ng/mL, and con-
versely, we observed five patients with GG and three patients 
with GT genotypes with subtherapeutic NVP Cmin (p  = 
0.001). No difference in median NVP Cmin was observed for 
CYP3A metabolizer (extensive: 4522  ng/mL (IQR  =  3932–
6135  ng/mL), intermediate: 5332  ng/mL (IQR  =  3988–
6852) and poor: 4840  ng/mL (IQR  =  3703–7430); p  = 
0.572).
Linear regression model
In the final linear regression model (Table 3), factors signifi-
cantly associated with a higher NVP Cmin were T allele of 
CYP2B6 rs3745274 (β  =  0.328, 95% confidence interval 
(CI)  =  0.172–0.484; p  <  0.0001), older age (β  =  0.362, 95% 
CI  =  0.193–0.532; p  <  0.0001) and HCV coinfection (β  = 
0.161, 95% CI  =  0.006–0.315; p  <  0.041). A trend was also 
observed for female gender (β  =  0.135, 95% CI  =  0.024–
0.294; p  =  0.096) in association with higher NVP Cmin.
Discussion
In a prevalently Caucasian population of HIV-positive 
patients receiving NVP-based regimens at a dose of 400  mg 
once a day, we found a large interindividual variability in 
NVP plasma concentration, a finding which is consistent 
with previous reports.16
The usual target of NVP Cmin required to obtain virologi-
cal control is >3000  ng/mL.17 NVP plasma concentrations 
lower than this threshold may result in reduced viral control 
with the development of non-nucleoside reverse-tran-
scriptase inhibitors–resistant mutations.18 In our study, only 
eight patients (5.6%) showed subtherapeutic levels of NVP, 
and there were no significant differences in the rate of viro-
logical control at the time of NVP Cmin determination in this 
group of patients as compared to those with NVP Cmin within 
therapeutic range. This finding could be expected in a cohort 
of patients in stable NVP-based regimen with a long NVP 
treatment.
Table 1. Summary of patient demographics and clinical 
characteristics of patients included in the model.
Total (N  =  143)
Female, n (%) 55 (38.5)
Age (years), median (IQR) 47.7 (42.5–52.8)
Caucasian, n (%) 132 (92.3)
BMI (kg/m2), median (IQR) 23.1 (20.8–24.5)
HCV coinfection, n (%) 32 (22.4)
HBV coinfection, n (%) 6 (4.2)
ARV Backbone, n (%)
 ABC 11 (7.7)
 AZT/DDI/D4T 69 (48.2)
 TDF 55 (38.5)
 Other 8 (5.6)
CYP2B6 c.516 G>T rs3745274, n (%)
 GG 72 (50.3)
 GT 60 (42.0)
 TT 11 (7.7)
CYP3Aa, n (%)
 E 16 (11.2)
 I 114 (79.7)
 P 10 (7.0)
 Nd 3 (2.1)
n: number of patients; IQR: interquartile range; BMI: body mass index; 
ARV: antiretroviral; ABC: abacavir; AZT/DDI/D4T: zidovudine/didano-
sine/stavudine; E: extensive metabolizer; I: intermediate metabolizer; P: 
poor metabolizer; nd: not determined.
aCYP3A4*22/rs35599367 and CYP3A5*3/rs776746 are combined geno-
types for comprehensive functional evaluation.14,15
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Moreover, the association of NVP concentrations and tox-
icity is still debated.12,19 In a study conducted in Spain, an 
association between increased liver transaminases and NVP 
Cmin concentrations greater than 6000  ng/mL was observed,12 
but other studies conducted on population of different ethnic-
ity did not find an association between NVP Cmin and hepato-
toxicity.19–21 In our cohort, we did not observe a correlation 
between AST and ALT levels and NVP Cmin, thus supporting 
the evidence that other pathogenetic mechanism unrelated to 
NVP concentration are involved in NVP-induced liver toxic-
ity.19 Although on one hand our findings support the long-
term safety of NVP-based regimens also in patients with 
elevated Cmin concentrations, on the other hand we cannot 
infer about the correlation between NVP Cmin and early NVP-
induced liver toxicity due to the long median time of NVP 
exposure at the time of NVP Cmin determination in our cohort.
The role of polymorphisms in the CYP2B6 gene in influ-
encing NVP plasma concentrations is well established.6,7,13 
Specifically, the presence of the T allele at the position c.516 
of CYP2B6 has been associated with increased NVP plasma 
concentrations in populations of different ethnicity.13 In 
agreement with previous studies, we observed a genotype-
dose effect with an increment of NVP plasma concentration 
accordingly to the copy number in carriers of the CYP2B6 
c.516 T allele.9 None of our patients with CYP2B6 
Table 2. Patients’ characteristics according to NVP Cmin concentrations.
NVP Cmin  <  3000  ng/mL
8 (5.6%)
NVP Cmin  =  3000–6000  ng/mL
74 (51.7%)
NVP Cmin  >  6000  ng/mL
61 (42.7%)
p
Female, n (%) 3 (37.5) 24 (32.4) 28 (45.9) 0.258
Age (years), median (IQR) 43.1 (36.3–46.1) 46.9 (40.7–52.2) 49.3 (43.4–56.0) 0.031
Caucasian, n (%) 7 (87.5) 69 (93.2) 56 (91.8) 0.570
Weight (kg), median (IQR) 75 (66–79) 66 (60–75) 67 (58–71) 0.320
BMI (kg/m2), median (IQR) 23.5 (21.4–24.0) 23.4 (20.3–24.5) 22.0 (20.9–24.3) 0.842
HCV coinfection, n (%) 0 (0.0) 14 (18.9) 18 (29.5) 0.106
HBV coinfection, n (%) 1 (12.5) 2 (2.7) 3 (4.9) 0.271
HIV-RNA  <  37  cps/mL, n (%) 7 (87.5) 71 (95.9) 58 (95.1) 0.499
AST (U/L), median (IQR) 24 (21–33) 26 (22–28) 28 (22–34) 0.519
ALT (U/L), median (IQR) 26 (19–43) 28 (20–33) 35 (23–48) 0.191
ARV backbone, n (%)
 ABC 0 (0.0) 8 (10.8) 3 (4.9) 0.776
 AZT/DDI/D4T 4 (50.0) 32 (43.2) 33 (54.1)  
 TDF 4 (50.0) 29 (39.2) 22 (36.1)  
 Other 0 (0.0) 5 (6.8) 3 (4.9)  
CYP2B6 c.516 G>T rs3745274, n (%)
 G/G 5 (62.5) 48 (64.9) 19 (31.1) <0.001
 G/T 3 (37.5) 25 (33.8) 32 (52.5)  
 T/T 0 (0.0) 1 (1.3) 10 (16.4)  
CYP3Aa, n (%)
 E 1 (12.5) 10 (13.5) 5 (8.2) 0.807
 I 6 (75.0) 57 (77.0) 51 (83.6)  
 P 1 (12.5) 5 (6.8) 4 (6.6)  
 nd 0 (0.0) 2 (2.7) 1 (1.6)  
n: number of patients; IQR: interquartile range; BMI: body mass index; cps: copies; ARV: antiretroviral; ABC: abacavir; AZT/DDI/D4T: zidovudine/didano-
sine/stavudine; E: extensive metabolizer; I: intermediate metabolizer; P: poor metabolizer; nd: not determined; AST: aspartate aminotransferase; ALT: 
alanine aminotransferase.
aCYP3A4*22/rs35599367 and CYP3A5*3/rs776746 are combined genotypes for comprehensive functional evaluation.14,15
Italics indicate p value with statistical significance.
Figure 1. Nevirapine plasma trough concentration according to 
CYP2B6 516 G>T genotypes. Box and Whiskers plots represent 
the first quartile, the median, the third quartile, the lowest datum 
still within 1.5 IQR of the lower quartile and the highest datum 
still within 1.5 IQR of the upper quartile (+  =  mean).
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TT genotypes showed subtherapeutic levels of NVP Cmin, 
confirming the importance of the presence of at least one T 
alleles in determining NVP Cmin above the therapeutic 
threshold also in Caucasian patients.9
Although CYP3A4 and CYP3A5 are involved in the 
metabolism of NVP, we did not find any significant associa-
tion between polymorphisms of these genes (even consider-
ing their combined effect) and NVP plasma concentration, 
and this is consistent with the findings of previous studies.13 
CYP3A4 and CYP3A5 account for a 90% sequence homol-
ogy with a relevant overlap in substrate specificity.21 In 
African populations, CYP3A5 enzyme could play a consid-
erable role in the metabolism of NVP since it is expressed to 
higher levels when compared to Caucasians.8
Beyond genetic background, other patient-related factors, 
in particular sex, body weight and underlying liver disease, 
may affect NVP plasma exposure.16,22
Our data confirm the significant role of HCV infection in 
influencing NVP plasma levels. However, it should be con-
sidered that the effect of HCV coinfection on NVP plasma 
concentration may have a small impact in patient with a nor-
mal liver function.22,23 Thus, it is possible that hepatic func-
tion rather than HCV per se could represent a more reliable 
predictor of increased NVP plasma concentrations.24
Similar to results of the study by Wyen et al.,7 we found 
a significant association between age and higher NVP 
plasma concentration. The possible age-related NVP over-
exposure has to be taken into account when NVP is used in 
the contest of simplification strategy in particular with the 
possible use of NVP in an aging population with metabolic 
disorders.3,25,26
We also observed a trend for female gender and elevated 
NVP plasma concentration, as previously found in several 
independent studies.18,27 Conversely, we did not observe an 
association with NVP exposure and body weight as previ-
ously shown in other studies.9 This could partially be 
explained by the homogeneity of body weight in our cohort 
and by the possible link between the two variables (gender 
and body weight) in our model.
Our study accounts for several limitations. First, the 
mono-centric design may limit the generalizability of our 
findings. Second, the retrospective design could influence 
the selection of patients. In particular, we selected patients 
tolerant to NVP-based regimens excluding from the analysis 
patients who early interrupted the regimen after NVP start. 
Third, although our study suggests that patients on long-term 
effective NVP-containing regimens may be able to maintain 
virological suppression even with unfavorable genotypic 
profile and lower NVP concentrations, these results may be 
not generalizable to all patients, particularly those receiving 
NVP-based regimens as first-line therapy in whom virologi-
cal failure due to subtherapeutic drug levels has been well 
described. Fourth, it should be considered that the use of 
NVP in high-income countries has been dramatically 
decreased in recent years, and our data apply to limited num-
ber of patients. Finally, it is unlikely that our genetic tech-
nique is going to be applied in resource-limited setting, in 
contrast to higher income countries. This genetic methodol-
ogy could serve as proof-of-principle in further studies using 
newer compounds in development, in old and more recent 
classes.
Moreover, we evaluated only the well-known SNPs into 
the genes that directly affect NVP metabolism, but other 
SNPs or other CYPs regulatory genes may be involved.
Conclusion
Our study, conducted in a prevalent Caucasian population, 
reaffirms the importance of CYP2B6 genetic variants in 
influencing NVP plasma trough concentration. 
Furthermore, the importance of clinical covariates, such as 
older age and HCV coinfection, in determining exposure 
to NVP had been confirmed. Personalization of antiretro-
viral therapy is today reachable and overall our data 
Table 3. Univariate and multivariable regression analyses of factors associated with NVP plasma trough concentrations.
Univariate analysis Multivariate analysis
 β SD p β SD p
CYP2B6 c.516, T allele 0.341 0.079 <0.0001 0.328 0.079 <0.0001
BMI 0.016 0.086 0.848 −0.055 0.081 0.498
Patients’ age 0.241 0.082 0.004 0.362 0.086 <0.0001
Females 0.121 0.084 0.151 0.135 0.080 0.096
Caucasian patients 0.015 0.084 0.861 −0.069 0.081 0.396
HBV coinfection −0.073 0.084 0.387 −0.081 0.079 0.308
HCV coinfection 0.210 0.082 0.012 0.161 0.078 0.041
Backbone AZT/DDI/D4T versus ABC 0.056 0.164 0.735 −0.126 0.150 0.401
Backbone TDF versus ABC −0.007 0.163 0.963 −0.047 0.147 0.752
Other backbone versus ABC 0.040 0.108 0.712 −0.003 0.099 0.975
SD: standard deviation; BMI: body mass index; ARV: antiretroviral; ABC: abacavir; AZT/DDI/D4T: zidovudine/didanosine/stavudine; TDF: tenofovir diso-
proxil fumarate; HCV: hepatitis C virus; HBV: hepatitis B virus; NVP: nevirapine.
Italics indicate p value with statistical significance.
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support the potential of pharmacogenomics in selecting 
the most appropriate treatment for each patient. We 
acknowledge the fact that certain techniques are applied in 
high-resource countries which can afford them and not 
worldwide. This gap has to be filled and novel technolo-
gies have to be disseminated in every country where HIV-
positive subjects are cared for.
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